APMD Apnimed, Inc.

Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.

Bank of America sees a differentiated opportunity in a breakthrough sleep apnea pill.

Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.

Shares of Apnimed rose 8% Tuesday after BofA Securities initiated coverage of the company with a Buy rating and a $41 price target. The rating is based on a risk-adjusted discounted cash flow analysis of Oxnimbi (AD109), Apnimed's sole asset and an oral therapy for obstructive sleep apnea...

Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.

The trial met both endpoints in the readout, removing the inconclusive outcome management itself had flagged, and short sellers in the stock took a record single-session loss.

Apnimed (NasdaqGS:APMD) has been added to the NASDAQ Composite Index, increasing its visibility among index-following investors. Inclusion in the index can lead to higher trading liquidity as more funds and investors track or reference the NASDAQ Composite. The move is often viewed as recognition of a company’s progress and operational milestones within the public markets. For a broader view on companies gaining fresh attention from index inclusions and other milestones, explore the wider...

Stock market leaders are becoming plentiful as the S&P 500 probes all-time highs. Recent IPO Bending Spoons clears an IPO base.